NCT02470234View on ClinicalTrials.gov

Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 30, 2016

Primary Completion Date

July 20, 2017

Study Completion Date

August 7, 2017

Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
DRUG

Methylphenidate HCl ER Capsules, 10 mg

Methylphenidate Hydrochloride Extended-Release Capsules, 10 mg administered once daily in the morning

DRUG

Methylphenidate HCl ER Capsules, 15 mg

Methylphenidate Hydrochloride Extended-Release Capsules, 15 mg administered once daily in the morning

DRUG

Methylphenidate HCl ER Capsules, 20 mg

Methylphenidate Hydrochloride Extended-Release Capsules, 20 mg administered once daily in the morning

Trial Locations (2)

27705

Duke Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham

33143

Qps-Mra, Llc, South Miami

All Listed Sponsors
lead

Rhodes Pharmaceuticals, L.P.

INDUSTRY

NCT02470234 - Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD | Biotech Hunter | Biotech Hunter